Advertisement

Cytosorbents Corporation CTSO

Set alert

Price alert · CTSO

All alert types
4.54 USD 0.00 -0.11%

At close · Oct 30

4.54 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
4.54 × 3
Ask
4.69 × 1
4.35 Day range 4.70
3.06 52-week range 16.74
YTD
-64.48%
1 year
-70.97%
Open
4.39
Prev close
4.54
Mkt cap
14.31M
Vol
24.11K
Avg vol
33.22K
EPS
-5.80
P/E
0.00
Div yield
0.00%
More statistics
Low
4.35
High
4.70
Forward P/E
-5.99
Beta
0.56
Short ratio
9.57
Inst. own
33.29%
Dividend
0.00
Ex-div date
50-d avg
0.95762
200-d avg
0.981655
1y target
5.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 4, 2024Rating: EF Hutton · Buy → Buy
  • Nov 7, 2024Earnings: -0.08; estimate -0.07; surprise -14.29%
  • Nov 8, 2024Rating: EF Hutton · Buy → Buy
  • Nov 11, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
  • Nov 12, 2024Rating: D. Boral Capital · Buy → Buy
  • Sep 8, 2026Split: 1 for 20
Signals (96)
NameDateAgo
SMA: BearishOct 23, 20261 week ago
SMA: BullishOct 22, 20261 week ago
MACD: Buy SignalOct 16, 20262 weeks ago
MACD: Sell SignalOct 14, 20262 weeks ago
MACD: Buy SignalOct 12, 20262 weeks ago
RSI: OversoldSep 23, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BearishSep 3, 20261 month ago
SMA: BullishSep 2, 20262 months ago
MACD: Buy SignalSep 2, 20262 months ago
MACD: Sell SignalAug 27, 20262 months ago
MACD: Buy SignalAug 24, 20262 months ago
MACD: Sell SignalAug 20, 20262 months ago
SMA: BearishAug 17, 20262 months ago
SMA: BullishAug 14, 20262 months ago
MACD: Buy SignalJul 6, 20263 months ago
MACD: Sell SignalJun 29, 20264 months ago
MACD: Buy SignalJun 16, 20264 months ago
RSI: OversoldJun 10, 20264 months ago
MACD: Sell SignalJun 8, 20264 months ago
RSI: OversoldJun 8, 20264 months ago
MACD: Buy SignalJun 3, 20265 months ago
RSI: OversoldMay 20, 20265 months ago
MACD: Sell SignalMay 13, 20265 months ago
MACD: Buy SignalMay 11, 20265 months ago
MACD: Sell SignalMay 6, 20265 months ago
MACD: Buy SignalApr 10, 20266 months ago
SMA: BearishMar 25, 20267 months ago
SMA: BullishMar 24, 20267 months ago
SMA: BearishMar 16, 20267 months ago
MACD: Sell SignalMar 12, 20267 months ago
RSI: OverboughtMar 9, 20267 months ago
RSI: OverboughtMar 5, 20268 months ago
RSI: OverboughtMar 3, 20268 months ago
SMA: BullishFeb 23, 20268 months ago
MACD: Buy SignalFeb 23, 20268 months ago
MACD: Sell SignalFeb 11, 20268 months ago
MACD: Buy SignalFeb 9, 20268 months ago
MACD: Sell SignalFeb 5, 20268 months ago
MACD: Buy SignalFeb 4, 20269 months ago
MACD: Sell SignalJan 29, 20269 months ago
MACD: Buy SignalJan 28, 20269 months ago
MACD: Sell SignalJan 26, 20269 months ago
SMA: BearishJan 20, 20269 months ago
SMA: BullishJan 16, 20269 months ago
SMA: BearishJan 15, 20269 months ago
SMA: BullishJan 13, 20269 months ago
MACD: Buy SignalJan 5, 202610 months ago
MACD: Sell SignalDec 31, 202510 months ago
SMA: BearishDec 23, 202510 months ago
SMA: BullishDec 22, 202510 months ago
MACD: Buy SignalDec 22, 202510 months ago
MACD: Sell SignalDec 12, 202510 months ago
SMA: BearishNov 26, 202511 months ago
SMA: BullishNov 25, 202511 months ago
MACD: Buy SignalNov 21, 202511 months ago
RSI: OversoldNov 5, 202512 months ago
MACD: Sell SignalOct 10, 20251 year ago
SMA: BearishOct 9, 20251 year ago
SMA: BullishOct 8, 20251 year ago
SMA: BearishOct 6, 20251 year ago
SMA: BullishOct 2, 20251 year ago
MACD: Buy SignalSep 22, 20251 year ago
MACD: Sell SignalSep 15, 20251 year ago
MACD: Buy SignalSep 4, 20251 year ago
MACD: Sell SignalAug 21, 20251 year ago
SMA: BearishAug 20, 20251 year ago
SMA: BullishAug 11, 20251 year ago
MACD: Buy SignalAug 8, 20251 year ago
SMA: BearishJul 22, 20251 year ago
SMA: BullishJul 18, 20251 year ago
SMA: BearishJul 17, 20251 year ago
SMA: BullishJul 3, 20251 year ago
SMA: BearishJul 2, 20251 year ago
MACD: Sell SignalJul 2, 20251 year ago
RSI: OverboughtJun 23, 20251 year ago
RSI: OverboughtJun 16, 20251 year ago
SMA: BullishJun 3, 20251 year ago
MACD: Buy SignalMay 28, 20251 year ago
RSI: OversoldMay 14, 20251 year ago
MACD: Sell SignalMay 2, 20251 year ago
SMA: BearishApr 30, 20251 year ago
SMA: BullishApr 21, 20251 year ago
MACD: Buy SignalApr 15, 20251 year ago
SMA: BearishMar 21, 20251 year ago
MACD: Sell SignalMar 21, 20251 year ago
MACD: Buy SignalMar 17, 20251 year ago
SMA: BullishMar 12, 20251 year ago
SMA: BearishMar 7, 20251 year ago
SMA: BullishMar 5, 20251 year ago
SMA: BearishMar 4, 20251 year ago
MACD: Sell SignalFeb 24, 20251 year ago
RSI: OverboughtFeb 13, 20251 year ago
MACD: Buy SignalFeb 12, 20251 year ago
MACD: Sell SignalJan 28, 20251 year ago
MACD: Buy SignalDec 27, 20241 year ago

Key statistics

Market cap
46.07M
Enterprise value
71.15M
Trailing P/E
0.00
Forward P/E
-5.99
PEG ratio
0.00
Price / sales
1.22
Price / book
3.51
EPS (TTM)
-0.36
Beta
0.56
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-49.47%
Revenue (TTM)
37.74M
Revenue growth
6.60%
Free cash flow
-11.95M
Total cash
5.69M
Total debt
26.81M
Return on equity
-118.50%
Shares outstanding
54.95M
Short % of float
2.58%
50-day average
0.95762
200-day average
0.981655

Analyst view

Consensus: buy

Buy
Price target (mean) 5.00 +10.1% upside
Target (low)
1.00
Target (mean)
5.00
Target (high)
10.00
Ratings (0m) 2 1 buy · 1 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.07.

Earnings history

Financials — quick view

All financials
CTSO Revenue — quarterly 9.63M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CTSO Net income — quarterly -4.42M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CTSO EPS — quarterly -1.40
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CTSO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.07-0.08-0.01-14.29%
Aug 13, 2024Jun 1, 2024-0.09-0.08+0.01+11.11%
May 9, 2024Mar 1, 2024-0.12-0.120.000.00%
Mar 14, 2024Dec 1, 2023-0.14-0.12+0.02+14.29%
Nov 9, 2023Sep 1, 2023-0.12-0.21-0.09-75.00%
Aug 1, 2023Jun 1, 2023-0.11-0.14-0.03-27.27%

Upgrades / downgrades

CTSO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 12, 2024D. Boral CapitalmainBuyBuy
Nov 11, 2024HC Wainwright & Co.reitNeutralNeutral
Nov 8, 2024EF HuttonmainBuyBuy
Nov 4, 2024EF HuttonmainBuyBuy
Oct 22, 2024EF HuttonmainBuyBuy
Oct 1, 2024EF HuttonmainBuyBuy

About Cytosorbents Corporation

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on CTSO — it syncs with the Stock Master app.

Insider holders

CTSO insider holders
InsiderRelationLatest transactionDateShares held
BATOR MICHAEL G.DirectorPurchaseDec 12, 2023125,394
BLOCH KATHLEEN PChief Financial OfficerStock Award(Grant)Apr 1, 2024532,941
CAPPONI VINCENT JPresidentStock Award(Grant)Apr 1, 2024665,134
CHAN PHILLIP PChief Executive OfficerStock Award(Grant)Apr 1, 20241,164,700
DELIARGYRIS EFTHYMIOSOfficerStock Award(Grant)Apr 1, 2024409,433
JONES EDWARD RAYMOND M.D.DirectorPurchaseDec 12, 202388,834

Institution ownership

CTSO institution ownership
Holder% heldSharesValueReported
Avenir Corp5.44%2,975,5592.49MSep 29, 2024
Skylands Capital, LLC5.04%2,755,4272.31MSep 29, 2024
Granahan Investment Management LLC3.83%2,094,8821.76MSep 29, 2024
Vanguard Group Inc3.57%1,949,5511.63MSep 29, 2024
Neuberger Berman Group, LLC3.26%1,781,3601.49MSep 29, 2024
Sargent Investment Group, LLC2.97%1,626,2471.36MSep 29, 2024

Fund ownership

CTSO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.38%1,302,2161.09MSep 29, 2024
Neuberger & Berman Intrinsic Value Fd1.33%726,136608.79KOct 30, 2024
Vanguard Extended Market Index Fund1.04%568,233476.41KSep 29, 2024
JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd0.99%541,568454.05KSep 29, 2024
USAA Mutual Fund Tr-Small Cap Stock Fund0.65%357,974300.13KJul 30, 2024
Fidelity Extended Market Index Fund0.47%259,695217.73KOct 30, 2024
Advertisement